MagicMed

The psychedelics sector has closed one of its largest M&As since its inception. On Friday, Enveric Biosciences (NASDAQ: ENVB) confirmed that its previously announced acquisition of MagicMed Industries has gone through. Enveric is a biotech company working with cannabinoids and other molecules...

MagicMed Industries' focus is on creating new molecules based on psychedelics, said CEO Dr. Joseph Tucker — but with better attributes. Those attributes help take molecules from the discovery to the preclinical phase, Tucker said Friday at the virtual Benzinga Cannabis...

Co-written by Andrew Ward and Natan Ponieman The race is continually heating up in the psychedelics space. An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment. The race has...

This article was originally published on Microdose Psychedelic Insights and appears here with permission. The innovative team at MagicMed, in pursuit of expanding their novel psychedelic derivative patent library (cleverly dubbed the “Psybrary™”), has formed a...

ATAI Launches Subsidiary Focused on DMT Psychedelics and biotech company ATAI Life Sciences announced the launch of Viridia Life Sciences, a wholly-owned subsidiary that will be dedicated to the study and production of the DMT molecule (N,N-Dimethyltryptamine). DMT is the active ingredient in...